 - Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing or another treatment of an anti-CD20 monoclonal antibody regimen, and relapse more than 6 months from the last administration of rituximab-containing or another treatment of an anti-CD20 antibody-containing therapy. 